Tomoko Tachibana
Chiba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Local therapy with hypoxia-targeting radiopharmaceutical [64Cu]Cu-ATSM in high-grade glioma patient-derived xenograft models.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: September 15, 2025
[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [64Cu]Cu-ATSM to Patients].
Journal: Kaku igaku. The Japanese journal of nuclear medicine
Published: January 29, 2025
64Cu2+ Complexes of Tripodal Amine Ligands' In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 29, 2024
Trace Metal Impurities Effects on the Formation of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM).
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 15, 2023
An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors.
Journal: International journal of molecular sciences
Published: October 04, 2023
Process to Remove the Size Variants Contained in the Antibody-Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 22, 2023
Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with 64Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model.
Journal: Journal of cancer research and therapeutics
Published: September 23, 2022
Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET.
Journal: Pharmaceutics
Published: August 09, 2022
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.
Journal: International journal of molecular sciences
Published: April 20, 2022
Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography.
Journal: Pharmaceutics
Published: December 07, 2021
Identification and quantitative structure-activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM.
Journal: Nuclear medicine and biology
Published: November 30, 2021
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy.
Journal: Pharmaceutics
Published: September 09, 2021
Last Updated: 09/26/2026